IP Library Granted Patent US 7,928,255
Granted Patent B2
US 7,928,255 · App. 11/585,501 · Granted Apr 19, 2011

Intermediates for the preparation of lipoxin A

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,928,255
App. No.
11/585,501
Granted
Apr 19, 2011
Kind
B2
Abstract

This invention is directed to lipoxin A 4 analogs of the following formula (I) and (II): wherein R 1 , R 2 , R 3 , R 4 and R 5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.

Claims (14)

1. A compound of the following formula:

wherein,

R 5 is aryl (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halo, haloalkyl and haloalkoxy) or aralkyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halo, haloalkyl and haloalkoxy);

R 7 is alkyl, cycloalkyl, aryl, or aralkyl; and

R 10 is a straight or branched alkylene chain, a straight or branched alkenylene chain, a straight or branched alkynylene chain, or cycloalkylene;

as a single stereoisomer, a mixture of stereoisomers, or a racemic mixture of stereoisomers.

2. The compound according to claim 1 wherein

R 5 is aryl (optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, halo, and haloalkoxy);

R 7 is alkyl; and

R 10 is a straight or branched alkylene chain.

3. The compound according to claim 2 wherein R 7 is tert-butyl and R 10 is methylene.

4. The compound according to claim 3 wherein R 5 is optionally-substituted phenyl.

5. The compound according to claim 4 having the formula:

6. The compound tert-butyl 2-{[(4E,6E,10E)-(2S,3R,12S)-13-(4-fluorophenoxy)-2,3,12-trihydroxytrideca-4,6,10-trien-8-yn-1-yl]oxy}acetate, according to claim 5 .

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2019
From: BAYER INTELLECTUAL PROPERTY GMBH
To: THE BRIGHAM & WOMEN'S HOSPITAL, INC.
Reel/Frame 048753/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2014
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 033292/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2014
From: BAUMAN, JOHN G.; GUILFORD, WILLIAM J.; PARKINSON, JOHN F.; SKUBALLA, WERNER; SUBRAMANYAM, BABU
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 033120/0735 →
CHANGE OF NAME Recorded Jul 1, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030719/0668 →
CHANGE OF NAME Recorded Nov 11, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 029277/0286 →
CHANGE OF NAME Recorded Jul 27, 2009
From: SCHERING AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023010/0253 →